Clinical Trials Logo

Filter by:
NCT ID: NCT05257408 Active, not recruiting - Clinical trials for Peritoneal Neoplasms

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

Start date: June 29, 2022
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate progression-free survival (PFS) by blinded independent central review (BICR) in patients treated with intermittent regimen of relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel monotherapy.

NCT ID: NCT05257083 Recruiting - Multiple Myeloma Clinical Trials

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

CARTITUDE-6
Start date: October 10, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple myeloma patients.

NCT ID: NCT05256732 Completed - Clinical trials for Healthy Volunteer Study

Study of AT-527 in Healthy Subjects Under Fasting Conditions or With a Meal

Start date: February 22, 2022
Phase: Phase 1
Study type: Interventional

This study will assess the safety, tolerability and pharmacokinetics (PK) of AT-527 following oral administration under fasting conditions or with a meal in healthy adult subjects

NCT ID: NCT05256654 Active, not recruiting - Dyslipidemias Clinical Trials

A Study of LY3561774 in Participants With Mixed Dyslipidemia

PROLONG-ANG3
Start date: July 20, 2022
Phase: Phase 2
Study type: Interventional

This a multicenter, Phase 2b, double-blind, placebo-controlled, parallel group study to provide data on efficacy and safety of LY3561774 administered subcutaneously at various doses in participants with mixed dyslipidemia and on a stable dose of a statin.

NCT ID: NCT05256628 Not yet recruiting - Clinical trials for Femoroacetabular Impingement Syndrome

Early Versus Delayed Weightbearing in Femoroacetabular Impingement Syndrome Patients

FASTHIP
Start date: September 2022
Phase: N/A
Study type: Interventional

Femoroacetabular impingement syndrome (FAIS) is a condition caused by an abnormal bone structure that causes the bones on either side of the hip joint to impinge on each other during certain movements, thus causing pain. This condition can be surgically treated with hip arthroscopy. For patients undergoing hip arthroscopy, there are currently two protocols related to how they may bear their weight after surgery: 1) Delayed Weightbearing: Patients use crutches and put very little weight on the surgical side. After 6 weeks, they are able to bear weight, 2) Immediate Weightbearing: Patients bear weight on the affected side, as tolerated, immediately after surgery with crutches for additional support. They are then permitted to stop using the crutches in the weeks after surgery as they feel comfortable and are stable on the operative leg. The purpose of this study is to determine whether immediate or delayed weightbearing protocols following hip arthroscopy impact patient outcomes and complication rates. Participants will be randomly allocated into one of the two aforementioned groups, and followed up for 2 years to assess function and patient-reported outcomes.

NCT ID: NCT05256615 Recruiting - Diabetes Clinical Trials

Exercise Timing and Gestational Diabetes

Start date: January 1, 2020
Phase: N/A
Study type: Interventional

The aim of this study is to understand if the timing of exercise around food intake can help improve blood sugar management in pregnant individuals with diabetes.

NCT ID: NCT05256589 Completed - Clinical trials for Sars-CoV-2 Infection

Clinical Evaluation of the SONA Saliva C-19 Rapid Self-Test for the Detection of COVID-19

Start date: April 19, 2022
Phase: N/A
Study type: Interventional

The Sona Saliva C-19 Rapid Self-Test is a lateral flow assay intended for detection of the SARS-CoV-2 virus. Performance of the Sona Saliva C-19 Rapid Test assay will be assessed by comparison to an RT-PCR reference method.

NCT ID: NCT05256303 Completed - Asthma Clinical Trials

Rural Hospital-Level Care at Home for Acutely Ill Adults

Start date: February 16, 2022
Phase: N/A
Study type: Interventional

This study examines the implications of providing hospital-level care in rural homes.

NCT ID: NCT05256134 Terminated - Alzheimers Disease Clinical Trials

A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD)

SKYLINE
Start date: April 19, 2022
Phase: Phase 3
Study type: Interventional

A study to evaluate the efficacy and safety of gantenerumab in amyloid-positive, cognitively unimpaired participants at risk for or at the earliest stages of AD. The planned number of participants for this study is approximately 1200 participants randomized in a 1:1 ratio to receive either gantenerumab or placebo (600 participants randomized to gantenerumab and 600 participants randomized to placebo).

NCT ID: NCT05255679 Completed - Clinical trials for Acute Spinal Cord Injury

Early FES Cycling in Acute Spinal Cord Injury for Neuromuscular Preservation and Neurorecovery

Start date: April 21, 2021
Phase: N/A
Study type: Interventional

Spinal cord injury (SCI) is a devastating condition that often leads to paralysis and multiple health problems such as muscle wasting, bone loss and spasticity. Despite the paralysis, functional electrical stimulation (FES) on the skin surface muscles may produce muscle contractions. People who have had an SCI for a long time (chronic SCI) already use FES cycling to exercise, and it is known that it can reverse muscle atrophy and has a wide range of health benefits. Furthermore, animal research suggests that starting exercise training early after new SCI may promote spinal cord recovery. However, not much is known about early FES cycling in humans. Therefore, the investigators propose to study if early FES cycling could prevent muscle wasting, pain or spasticity, and help with spinal cord recovery. The study will recruit 36 participants with a new, acute SCI, between 14 and 21 days after their injury into 3 groups. An Early-FES group starts FES cycling early after injury (between 14 and 21 days after injury), and for a duration of 6 months. A Delayed-FES group starts FES cycling 3 months after enrolling in the study, and for a duration of 3 months. A Control group does not perform FES cycling. This pilot study will allow us to study if early FES cycling, in addition to normal care, has greater benefits on the preservation and recovery of the leg muscles and spinal cord function than delayed FES cycling or standard care only. The results of this pilot study may lead to the development of a larger study with early FES cycling after new SCI.